BRPI0507071A - derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase - Google Patents

derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase

Info

Publication number: BRPI0507071A
Authority: BR; Brazil
Prior art keywords: pyrimidin; treatment; dependent diseases; protein kinase; kinase dependent
Prior art date: 2004-01-22

Application number

BRPI0507071-6A

Other languages

English (en)

Portuguese (pt)

Inventor

Guido Bold

Andreas Floersheimer

Pascal Furet

Patricia Imbach

Keiichi Masuya

Joseph Schoepfer

Georg Martiny-Baron

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-22

Filing date

2005-01-21

Publication date

2007-06-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34807167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507071(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-01-21 Application filed by Novartis Ag filed Critical Novartis Ag

2007-06-19 Publication of BRPI0507071A publication Critical patent/BRPI0507071A/pt

Links

201000010099 disease Diseases 0.000 title abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
230000001419 dependent effect Effects 0.000 title abstract 3
102000001253 Protein Kinase Human genes 0.000 title abstract 2
108060006633 protein kinase Proteins 0.000 title abstract 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
-1 amine compounds Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
108091000080 Phosphotransferase Proteins 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Oncology (AREA)
Transplantation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0507071-6A 2004-01-22 2005-01-21 derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase BRPI0507071A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53822004P	2004-01-22	2004-01-22
PCT/EP2005/000602 WO2005070431A1 (fr)	2004-01-22	2005-01-21	Derives de pyrazolo[1,5-a]pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase

Publications (1)

Publication Number	Publication Date
BRPI0507071A true BRPI0507071A (pt)	2007-06-19

Family

ID=34807167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0507071-6A BRPI0507071A (pt)	2004-01-22	2005-01-21	derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase

Country Status (17)

Country	Link
EP (1)	EP1708710A1 (fr)
JP (1)	JP2007519662A (fr)
KR (1)	KR20070009546A (fr)
CN (1)	CN1909908A (fr)
AR (1)	AR049769A1 (fr)
AU (1)	AU2005205915B2 (fr)
BR (1)	BRPI0507071A (fr)
CA (1)	CA2552885A1 (fr)
EC (1)	ECSP066718A (fr)
IL (1)	IL176737A0 (fr)
MA (1)	MA28400B1 (fr)
NO (1)	NO20063758L (fr)
PE (1)	PE20051089A1 (fr)
RU (1)	RU2006130003A (fr)
TN (1)	TNSN06226A1 (fr)
TW (1)	TW200528103A (fr)
WO (1)	WO2005070431A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7605155B2 (en) *	2002-09-04	2009-10-20	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en)	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) *	2002-09-04	2009-07-21	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0515026D0 (en) *	2005-07-21	2005-08-31	Novartis Ag	Organic compounds
US20070082900A1 (en) *	2005-10-06	2007-04-12	Schering Corporation	Methods for inhibiting protein kinases
CN101321760A (zh) *	2005-10-06	2008-12-10	先灵公司	作为蛋白激酶抑制剂的吡唑并嘧啶
SI2495016T1 (sl)	2005-12-23	2020-04-30	Ariad Pharmaceuticals, Inc.	Biciklične heteroarilne spojine
MX2008011430A (es) *	2006-03-08	2008-09-18	Novartis Ag	Uso de derivados de pirazolo-[1,5a]-pirimidin-7-il-amina en el tratamiento de trastornos neurologicos.
WO2007109183A2 (fr) *	2006-03-20	2007-09-27	Novartis Ag	Mutations et polymorphismes de la tyrosine kinase 1 liée au fms
GB0606805D0 (en) *	2006-04-04	2006-05-17	Novartis Ag	Organic compounds
GB0606804D0 (en) *	2006-04-04	2006-05-17	Novartis Ag	Organic Compounds
EP2074127A1 (fr) *	2006-09-28	2009-07-01	Novartis AG	Dérivés pyrazolo[1,5-a]pyrimidine et leur utilisation thérapeutique
WO2008037477A1 (fr)	2006-09-29	2008-04-03	Novartis Ag	PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
EP1918291A1 (fr) *	2006-10-30	2008-05-07	Novartis AG	Dérives de pyrazole fusionnes substitués de 3-aminocarbonyle comme modulateurs de protéine kinase
JP5198562B2 (ja) *	2007-06-07	2013-05-15	メルク・シャープ・アンド・ドーム・コーポレーション	置換−３−アミノピラゾールの合成
US8591943B2 (en)	2009-04-09	2013-11-26	Merck Sharp & Dohme Corp.	Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
JP2013506669A (ja)	2009-09-30	2013-02-28	メルク・シャープ・アンド・ドーム・コーポレーション	Ｅｒｋ阻害剤である新規化合物
UY33227A (es) *	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
NZ604708A (en)	2010-05-20	2015-05-29	Array Biopharma Inc	Macrocyclic compounds as trk kinase inhibitors
AU2011290238B8 (en) *	2010-08-09	2015-09-03	Nb Health Laboratory Co. Ltd.	Inhibitor of casein kinase 1delta and casein kinase 1E
WO2012023143A1 (fr)	2010-08-19	2012-02-23	E. I. Du Pont De Nemours And Company	Pyrazoles fongicides
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
KR101404151B1 (ko) *	2011-11-25	2014-06-05	가톨릭대학교 산학협력단	안과 질환의 예방 및 치료용 약학 조성물
CN105906630B (zh) *	2015-04-06	2018-10-23	四川百利药业有限责任公司	用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
BR112018000808A2 (pt)	2015-07-16	2018-09-04	Array Biopharma Inc	compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
TWI752098B (zh)	2016-10-10	2022-01-11	美商亞雷生物製藥股份有限公司	作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN106588893A (zh) *	2016-12-01	2017-04-26	北京万全德众医药生物技术有限公司	维拉佐酮双氧化物的制备
US11168090B2 (en)	2017-01-18	2021-11-09	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (fr)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Inhibiteurs de ret
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh)	2017-10-10	2023-08-21	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740491A1 (fr)	2018-01-18	2020-11-25	Array Biopharma, Inc.	Composés de pyrrolo[2,3-d]pyrimidines substitués utilisés en tant qu'inhibiteurs de la kinase ret
WO2019143991A1 (fr)	2018-01-18	2019-07-25	Array Biopharma Inc.	Composés de pyrazolo[3,4-d]pyrimidine substitués utilisés en tant qu'inhibiteurs de la kinase ret
CN111615514B (zh)	2018-01-18	2022-10-11	奥瑞生物药品公司	作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3746071A4 (fr)	2018-01-29	2021-09-01	Merck Patent GmbH	Inhibiteurs de gcn2 et leurs utilisations
KR20200116481A (ko) *	2018-01-29	2020-10-12	메르크 파텐트 게엠베하	Gcn2 억제제 및 이의 용도
EP3849986B1 (fr)	2018-09-10	2022-06-08	Array Biopharma, Inc.	Composés hétérocycliques condensés comme inhibiteurs de kinases ret
CN109836428A (zh) *	2019-02-27	2019-06-04	华东师范大学	具有免疫抑制活性的吡唑[4,3-d]嘧啶衍生物及用途
US20210008173A1 (en) *	2019-07-10	2021-01-14	Musc Foundation For Research Development	Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
KR102598203B1 (ko)	2019-11-25	2023-11-03	암젠 인크	델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법
PE20250663A1 (es) *	2022-02-08	2025-03-04	Theras Inc	Compuestos con estructura en t formada por al menos cuatro ciclos para usar en el tratamiento del cancer y otras indicaciones
CN114751910B (zh) *	2022-05-17	2023-02-24	重庆文理学院	一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用
CN117843642B (zh) *	2022-10-09	2026-04-10	麦科萨药业(苏州)有限公司	一种双官能化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3130633A1 (de) *	1981-08-01	1983-02-17	Basf Ag, 6700 Ludwigshafen	7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
KR100191774B1 (ko) *	1991-04-22	1999-06-15	오스카 아끼히꼬	피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
US5707997A (en) *	1994-06-21	1998-01-13	Otsuka Pharmaceutical Factory, Inc.	Pyrazolo 1,5-a!pyrimidine derivative
JP3163413B2 (ja) *	1994-06-21	2001-05-08	株式会社大塚製薬工場	鎮痛剤
WO1998010590A1 (fr) *	1996-09-02	1998-03-12	Sony Corporation	Dispositif et procede de transmission d'un signal video
NZ539163A (en) *	2002-09-04	2007-03-30	Schering Corp	Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors
KR20050057139A (ko) *	2002-09-04	2005-06-16	쉐링 코포레이션	사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘

2005
- 2005-01-20 PE PE2005000080A patent/PE20051089A1/es not_active Application Discontinuation
- 2005-01-20 AR ARP050100208A patent/AR049769A1/es unknown
- 2005-01-21 JP JP2006550056A patent/JP2007519662A/ja active Pending
- 2005-01-21 WO PCT/EP2005/000602 patent/WO2005070431A1/fr not_active Ceased
- 2005-01-21 KR KR1020067014683A patent/KR20070009546A/ko not_active Withdrawn
- 2005-01-21 CN CNA2005800030379A patent/CN1909908A/zh active Pending
- 2005-01-21 RU RU2006130003/15A patent/RU2006130003A/ru not_active Application Discontinuation
- 2005-01-21 BR BRPI0507071-6A patent/BRPI0507071A/pt not_active IP Right Cessation
- 2005-01-21 AU AU2005205915A patent/AU2005205915B2/en not_active Ceased
- 2005-01-21 TW TW094101852A patent/TW200528103A/zh unknown
- 2005-01-21 CA CA002552885A patent/CA2552885A1/fr not_active Abandoned
- 2005-01-21 EP EP05706961A patent/EP1708710A1/fr not_active Withdrawn
2006
- 2006-07-06 IL IL176737A patent/IL176737A0/en unknown
- 2006-07-10 MA MA29182A patent/MA28400B1/fr unknown
- 2006-07-21 EC EC2006006718A patent/ECSP066718A/es unknown
- 2006-07-21 TN TNP2006000226A patent/TNSN06226A1/en unknown
- 2006-08-22 NO NO20063758A patent/NO20063758L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL176737A0 (en)	2006-10-31
CA2552885A1 (fr)	2005-08-04
RU2006130003A (ru)	2008-04-10
JP2007519662A (ja)	2007-07-19
AU2005205915A1 (en)	2005-08-04
KR20070009546A (ko)	2007-01-18
WO2005070431A1 (fr)	2005-08-04
PE20051089A1 (es)	2006-01-25
CN1909908A (zh)	2007-02-07
EP1708710A1 (fr)	2006-10-11
AU2005205915B2 (en)	2009-05-21
ECSP066718A (es)	2006-10-31
MA28400B1 (fr)	2007-01-02
TNSN06226A1 (en)	2007-12-03
TW200528103A (en)	2005-09-01
AR049769A1 (es)	2006-09-06
NO20063758L (no)	2006-10-23

Legal Events

Date	Code	Title	Description
2012-05-15	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2012-10-09	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

Publication	Publication Date	Title
BRPI0507071A (pt)	2007-06-19	derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase
BRPI0410563A (pt)	2006-06-20	derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
BR0315988A (pt)	2005-09-20	Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos
BRPI0411868B8 (pt)	2021-05-25	derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BR0307819A (pt)	2005-04-26	Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais
NO20072795L (no)	2007-06-01	Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
DK0836605T3 (da)	2002-05-13	Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
BR112014027244A2 (pt)	2017-06-27	derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1
MX2007005644A (es)	2007-06-05	Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa.
BR0211807A (pt)	2004-09-21	Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos
BRPI0418179A (pt)	2007-04-27	derivados de pirrolo[2,3-b] piridina ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas os compreendendo
GB0211649D0 (en)	2002-07-03	Organic compounds
WO2009071480A3 (fr)	2009-11-05	Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
MY143206A (en)	2011-03-31	1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
MX2009006613A (es)	2009-07-02	Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
HK1046679A1 (zh)	2003-01-24	酪氨酸蛋白激活酶syk的嘌呤衍生物抑制劑
WO2005005414A3 (fr)	2005-04-21	Derives de pyrazolyl-indole actifs en tant qu'inhibiteurs de kinase, procede de preparation correspondant et compositions pharmaceutiques les contenant
WO2005097135A3 (fr)	2006-02-16	Utilisation de derives de 9h-purine-2,6-diamine dans le traitement de maladies proliferantes et nouveaux derives de 9h-purine-2,6-diamine
BR0312722A (pt)	2005-05-10	Derivados de pirazol heterobicìclico como inibidores de qinase
DOP2005000014A (es)	2006-08-15	Derivados 1h-tieno[2, 3-c] pirazol utiles como inhibidores de quinasa
TW200502236A (en)	2005-01-16	Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
BRPI0508706A (pt)	2007-08-07	derivados de dicloro-fenil-pirido[2,3-d]pirimidina inusitados, sua fabricação e uso como agentes farmacêuticos
HK1097743A (en)	2007-07-06	Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
CU23566B7 (es)	2010-08-30	Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa
TH94267A (th)	2009-03-13	สารผสมเชิงเภสัชกรรมและวิธีการซึ่งใช้เทโมโซโลไมด์ และสารยับยั้งโปรตีนไคเนส